O	0	3	The
O	4	13	Minnesota
B-intervention	14	19	Green
I-intervention	20	23	Tea
I-intervention	24	29	Trial
I-intervention	30	31	(
I-intervention	31	35	MGTT
I-intervention	35	36	)
O	36	37	,
O	38	39	a
O	40	50	randomized
O	51	61	controlled
O	62	67	trial
O	68	70	of
O	71	74	the
O	75	83	efficacy
O	84	86	of
O	87	92	green
O	93	96	tea
O	97	104	extract
O	105	107	on
O	108	118	biomarkers
O	119	121	of
O	122	128	breast
O	129	135	cancer
O	136	140	risk
O	140	141	:
O	142	147	study
O	148	157	rationale
O	157	158	,
O	159	165	design
O	165	166	,
O	167	174	methods
O	174	175	,
O	176	179	and
O	180	191	participant
O	192	207	characteristics
O	207	208	.

O	209	212	The
O	213	222	Minnesota
O	223	228	Green
O	229	232	Tea
O	233	238	Trial
O	239	240	(
O	240	244	MGTT
O	244	245	)
O	246	249	was
O	250	251	a
O	252	262	randomized
O	262	263	,
O	264	271	placebo
O	271	272	-
O	272	282	controlled
O	282	283	,
O	284	290	double
O	290	291	-
O	291	298	blinded
O	299	304	trial
O	305	318	investigating
O	319	322	the
O	323	329	effect
O	330	332	of
O	333	338	daily
O	339	344	green
O	345	348	tea
O	349	356	extract
O	357	368	consumption
O	369	372	for
O	373	375	12
O	376	382	months
O	383	385	on
O	386	396	biomarkers
O	397	399	of
O	400	406	breast
O	407	413	cancer
O	414	418	risk
O	418	419	.

O	420	432	Participants
O	433	437	were
B-eligibility	438	445	healthy
I-eligibility	446	460	postmenopausal
I-eligibility	461	466	women
I-eligibility	467	469	at
I-eligibility	470	474	high
I-eligibility	475	479	risk
I-eligibility	480	482	of
I-eligibility	483	489	breast
I-eligibility	490	496	cancer
I-eligibility	497	500	due
I-eligibility	501	503	to
I-eligibility	504	509	dense
I-eligibility	510	516	breast
I-eligibility	517	523	tissue
I-eligibility	524	528	with
I-eligibility	529	538	differing
I-eligibility	539	547	catechol
I-eligibility	547	548	-
I-eligibility	548	549	O
I-eligibility	549	550	-
I-eligibility	550	567	methyltransferase
I-eligibility	568	569	(
I-eligibility	569	573	COMT
I-eligibility	573	574	)
I-eligibility	575	584	genotypes
O	584	585	.

O	586	589	The
O	590	602	intervention
O	603	606	was
O	607	608	a
O	609	614	green
O	615	618	tea
O	619	627	catechin
O	628	635	extract
O	636	646	containing
O	647	650	843
O	650	651	.
O	651	652	0
O	653	654	Â
O	654	655	±
O	656	658	44
O	658	659	.
O	659	660	0
O	661	663	mg
O	663	664	/
O	664	667	day
O	668	684	epigallocatechin
O	685	692	gallate
O	693	695	or
B-control	696	703	placebo
O	704	712	capsules
O	713	716	for
O	717	718	1
O	719	723	year
O	723	724	.

O	725	731	Annual
O	732	739	digital
O	740	749	screening
O	750	760	mammograms
O	761	765	were
O	766	774	obtained
O	775	777	at
O	778	786	baseline
O	787	790	and
O	791	796	month
O	797	799	12
O	799	800	,
O	801	804	and
O	805	812	fasting
O	813	818	blood
O	819	822	and
O	823	825	24
O	825	826	-
O	826	827	h
O	828	833	urine
O	834	841	samples
O	842	846	were
O	847	855	provided
O	856	858	at
O	859	867	baseline
O	868	871	and
O	872	874	at
O	875	881	months
O	882	883	6
O	884	887	and
O	888	890	12
O	890	891	.

O	892	899	Primary
O	900	909	endpoints
O	910	918	included
B-outcome-Measure	919	926	changes
I-outcome-Measure	927	929	in
I-outcome-Measure	930	937	percent
I-outcome-Measure	938	950	mammographic
I-outcome-Measure	951	958	density
O	958	959	,
B-outcome-Measure	960	971	circulating
I-outcome-Measure	972	982	endogenous
I-outcome-Measure	983	986	sex
I-outcome-Measure	987	995	hormones
O	995	996	,
O	997	1000	and
B-outcome-Measure	1001	1008	insulin
I-outcome-Measure	1008	1009	-
I-outcome-Measure	1009	1013	like
I-outcome-Measure	1014	1020	growth
I-outcome-Measure	1021	1027	factor
I-outcome-Measure	1028	1032	axis
I-outcome-Measure	1033	1041	proteins
O	1041	1042	;
O	1043	1052	secondary
O	1053	1062	endpoints
O	1063	1067	were
B-outcome-Measure	1068	1075	changes
I-outcome-Measure	1076	1078	in
I-outcome-Measure	1079	1086	urinary
I-outcome-Measure	1087	1096	estrogens
I-outcome-Measure	1097	1100	and
I-outcome-Measure	1101	1109	estrogen
I-outcome-Measure	1110	1121	metabolites
O	1122	1125	and
B-outcome-Measure	1126	1137	circulating
I-outcome-Measure	1138	1140	F2
I-outcome-Measure	1140	1141	-
I-outcome-Measure	1141	1153	isoprostanes
O	1153	1154	,
O	1155	1156	a
O	1157	1166	biomarker
O	1167	1169	of
O	1170	1179	oxidative
O	1180	1186	stress
O	1186	1187	.

O	1188	1191	The
O	1192	1196	MGTT
O	1197	1205	screened
O	1206	1210	more
O	1211	1215	than
O	1216	1219	100
O	1219	1220	,
O	1220	1223	000
O	1224	1234	mammograms
O	1235	1238	and
O	1239	1249	randomized
B-total-participants	1250	1251	1
I-total-participants	1251	1252	,
I-total-participants	1252	1255	075
O	1256	1268	participants
O	1269	1274	based
O	1275	1277	on
O	1278	1287	treatment
O	1288	1289	(
O	1289	1294	green
O	1295	1298	tea
O	1299	1306	extract
O	1307	1309	vs
O	1309	1310	.
O	1311	1318	placebo
O	1318	1319	)
O	1319	1320	,
O	1321	1331	stratified
O	1332	1334	by
O	1335	1339	COMT
O	1340	1348	genotype
O	1349	1357	activity
O	1358	1359	(
O	1359	1363	high
O	1364	1368	COMT
O	1369	1371	vs
O	1371	1372	.
O	1373	1376	low
O	1376	1377	/
O	1377	1389	intermediate
O	1390	1394	COMT
O	1395	1403	genotype
O	1404	1412	activity
O	1412	1413	)
O	1413	1414	.

O	1415	1416	A
O	1417	1422	total
O	1423	1425	of
B-total-participants	1426	1429	937
O	1430	1435	women
O	1436	1448	successfully
O	1449	1458	completed
O	1459	1462	the
O	1463	1468	study
O	1469	1472	and
O	1473	1476	138
O	1477	1484	dropped
O	1485	1488	out
O	1489	1490	(
O	1490	1497	overall
O	1498	1505	dropout
O	1506	1510	rate
O	1511	1512	=
O	1513	1515	12
O	1515	1516	.
O	1516	1517	8
O	1518	1519	%
O	1519	1520	)
O	1520	1521	.

O	1522	1524	In
O	1525	1529	this
O	1530	1535	paper
O	1536	1538	we
O	1539	1545	report
O	1546	1549	the
O	1550	1559	rationale
O	1559	1560	,
O	1561	1567	design
O	1567	1568	,
O	1569	1580	recruitment
O	1580	1581	,
O	1582	1593	participant
O	1594	1609	characteristics
O	1609	1610	,
O	1611	1614	and
O	1615	1622	methods
O	1623	1626	for
O	1627	1636	biomarker
O	1637	1640	and
O	1641	1652	statistical
O	1653	1661	analyses
O	1661	1662	.
